Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231146254> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4231146254 endingPage "689" @default.
- W4231146254 startingPage "689" @default.
- W4231146254 abstract "689 Background: The role of antiangiogenic agents in advanced RCC is well established. However, it is still not clear whether this benefit can be extrapolated to the adjuvant setting. In this meta-analysis of 3 randomized control trials (RCTs), we sought to determine the efficacy of these agents in RCC patients who underwent nephrectomy with high risk of relapse. Methods: We searched three databases, including Pubmed, Embase, and Cochrane Central Register of Controlled Trials to identify RCTs comparing antiangiogenic agents to placebo in post-nephrectomy RCC patients. We evaluated: 1) the effect of antiangiogenics in highest risk groups as defined by individual studies; 2) the role of each agent separately; and 3) the effect in clear-cell RCC population. Outcomes of interest included overall survival (OS) and disease-free survival (DFS). The overall effect was pooled using the DerSimonian and Laird random effects models Results: Three RCTs (N = 3693 patients) were identified. All studies were comparing placebo to antiangiogenics: sunitinib, sorafenib, and pazopanib. Overall, antiangiogenics did not improve DFS (HR 0.92, 95% CI 0.78 to 1.07) or OS (HR 0.99, 95% CI 0.79 to 1.25). These results persisted when restricting the analysis to patients with clear cell carcinoma and patients with highest risk of relapse. Similarly, sunitinib did not show any improvement in the entire studied group for either DFS (HR 0.89, 95% CI 0.67 to 1.19) or OS (HR 1.11, 95% CI 0.90 to 1.37). In addition, when restricting the analysis to the high risk group, sunitinib did not show any advantage in terms of DFS (HR 0.85, 95% CI 0.67 to 1.07) and OS (HR 1.04, 95% CI 0.83 to 1.31). Conclusions: Based on the available evidence, antiangiogenics do not seem to add an advantage over placebo in terms of OS and DFS in high risk RCC patients after nephrectomy. Further studies are needed to identify the patient population which might derive a benefit from antiangiogenics in the adjuvant setting." @default.
- W4231146254 created "2022-05-11" @default.
- W4231146254 creator A5034715033 @default.
- W4231146254 creator A5035100026 @default.
- W4231146254 creator A5058650905 @default.
- W4231146254 creator A5059366804 @default.
- W4231146254 creator A5065058975 @default.
- W4231146254 creator A5070784780 @default.
- W4231146254 date "2018-02-20" @default.
- W4231146254 modified "2023-09-27" @default.
- W4231146254 title "Adjuvant antiangiogenic agents in post-nephrectomy renal cell carcinoma (RCC): A systematic review and meta-analysis." @default.
- W4231146254 doi "https://doi.org/10.1200/jco.2018.36.6_suppl.689" @default.
- W4231146254 hasPublicationYear "2018" @default.
- W4231146254 type Work @default.
- W4231146254 citedByCount "0" @default.
- W4231146254 crossrefType "journal-article" @default.
- W4231146254 hasAuthorship W4231146254A5034715033 @default.
- W4231146254 hasAuthorship W4231146254A5035100026 @default.
- W4231146254 hasAuthorship W4231146254A5058650905 @default.
- W4231146254 hasAuthorship W4231146254A5059366804 @default.
- W4231146254 hasAuthorship W4231146254A5065058975 @default.
- W4231146254 hasAuthorship W4231146254A5070784780 @default.
- W4231146254 hasConcept C126322002 @default.
- W4231146254 hasConcept C141071460 @default.
- W4231146254 hasConcept C142724271 @default.
- W4231146254 hasConcept C143998085 @default.
- W4231146254 hasConcept C168563851 @default.
- W4231146254 hasConcept C204787440 @default.
- W4231146254 hasConcept C27081682 @default.
- W4231146254 hasConcept C2777472916 @default.
- W4231146254 hasConcept C2778019345 @default.
- W4231146254 hasConcept C2778439243 @default.
- W4231146254 hasConcept C2778695046 @default.
- W4231146254 hasConcept C2779490328 @default.
- W4231146254 hasConcept C2780091579 @default.
- W4231146254 hasConcept C2780227381 @default.
- W4231146254 hasConcept C2908647359 @default.
- W4231146254 hasConcept C71924100 @default.
- W4231146254 hasConcept C95190672 @default.
- W4231146254 hasConcept C99454951 @default.
- W4231146254 hasConceptScore W4231146254C126322002 @default.
- W4231146254 hasConceptScore W4231146254C141071460 @default.
- W4231146254 hasConceptScore W4231146254C142724271 @default.
- W4231146254 hasConceptScore W4231146254C143998085 @default.
- W4231146254 hasConceptScore W4231146254C168563851 @default.
- W4231146254 hasConceptScore W4231146254C204787440 @default.
- W4231146254 hasConceptScore W4231146254C27081682 @default.
- W4231146254 hasConceptScore W4231146254C2777472916 @default.
- W4231146254 hasConceptScore W4231146254C2778019345 @default.
- W4231146254 hasConceptScore W4231146254C2778439243 @default.
- W4231146254 hasConceptScore W4231146254C2778695046 @default.
- W4231146254 hasConceptScore W4231146254C2779490328 @default.
- W4231146254 hasConceptScore W4231146254C2780091579 @default.
- W4231146254 hasConceptScore W4231146254C2780227381 @default.
- W4231146254 hasConceptScore W4231146254C2908647359 @default.
- W4231146254 hasConceptScore W4231146254C71924100 @default.
- W4231146254 hasConceptScore W4231146254C95190672 @default.
- W4231146254 hasConceptScore W4231146254C99454951 @default.
- W4231146254 hasIssue "6_suppl" @default.
- W4231146254 hasLocation W42311462541 @default.
- W4231146254 hasOpenAccess W4231146254 @default.
- W4231146254 hasPrimaryLocation W42311462541 @default.
- W4231146254 hasRelatedWork W12291014 @default.
- W4231146254 hasRelatedWork W12636511 @default.
- W4231146254 hasRelatedWork W13397619 @default.
- W4231146254 hasRelatedWork W1411949 @default.
- W4231146254 hasRelatedWork W16128638 @default.
- W4231146254 hasRelatedWork W16388691 @default.
- W4231146254 hasRelatedWork W170953 @default.
- W4231146254 hasRelatedWork W3163895 @default.
- W4231146254 hasRelatedWork W5425512 @default.
- W4231146254 hasRelatedWork W6095507 @default.
- W4231146254 hasVolume "36" @default.
- W4231146254 isParatext "false" @default.
- W4231146254 isRetracted "false" @default.
- W4231146254 workType "article" @default.